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Abstract. The coexistence of multiple and synchronous primary
neoplasms in the same organ (including kidney) has only rarely
been described in the literature. We herein present a case of
collecting duct carcinoma (CDC) combined with papillary renal
carcinoma (RCC) having a 57-month disease-free survival. CDC is
a rather rare and aggressive neoplasm of the kidney. Sharing
probably the same embryological origin, synchronous or
metachronous association with in situ or papillary transitional cell
carcinoma (TCC) may be found; association with RCC has been
only once reported in the literature. The high incidence of c-erbB-2
oncogene amplification in CDC further characterizes this tumor as
a separate entity from renal cell carcinoma, and shows some genetic
characteristics in common with TCC. The histological diagnosis of
Bellini CDC can be confirmed by the positive immuno-
histochemical staining with a collecting duct marker and distal
tubule marker and negative staining with a proximal tubule marker.
Bellini’s collecting duct carcinoma (CDC) is an unusual renal
neoplasm with a poor prognosis. Its origin is not entirely
known, although it is thought to arise from the distal collecting
duct system, whereas clear cell renal carcinoma (RCC) may
originate from the proximal tubular epithelium (1). 
The coexistence of multiple and synchronous primary
neoplasms in the same organ (including kidney) has only
rarely been described in the literature. Some cases of rare
synchronous occurrence of transitional cell carcinoma
(TCC) and RCC have been reported. CDC was found to be
associated with TCC (2) and with RCC (3).
Recently, we had the opportunity to examine one such
case of synchronous CDC combined with RCC: the clinical,
radiological and histopathological findings are reported.
The clinical outcome was extremely favorable. 
Case Report
A 70-year-old man presented, for some months, lasting
inconstant hematuria and left flank pain. Ten years
previously, he had undergone an endoscopic procedure for
superficial TCC of the bladder. US and CT scan (Figure 1)
showed a left 5-cm-large renal mass developing towards and
infiltrating the upper major calyx with evidence of tumor
extension into the adjacent renal vein and artery. At
arteriography (Figure 2) the mass resulted avascular, while
retrograde pyelography (Figure 3) suggested it could be a
TCC involving the upper collecting system. Urinary cytology
showed papillary-like cell-aggregates. Radical nephrectomy
was performed, without ureterectomy, as frozen sections
showed that it was not TCC. Histopathological examination
demonstrated two tumors: one, centered on the renal
medulla, grossly infiltrating the upper major calyx (collecting
duct carcinoma), and another involving the upper renal pole
and extending to the capsule (papillary renal cell carcinoma).
After 57 months, the patient is still free of relapse.
Materials and Methods
The left nephrectomy specimen was examined grossly and
representative tissue blocks were taken from the tumors and the
adjacent renal parenchyma. They were fixed in 10% buffered
formalin and embedded in paraffin. Four-micrometer sections were
cut and stained with hematoxylin and eosin. Immunohistochemical
studies using a panel of antibodies (UEA-1, CK 7, CK 19 and c-
erb B2) were carried out (Table I).
Results
Gross findings. There was a solid tumor sited within the renal
medulla measuring 5.3 cm in maximum diameter. It had a
homogeneous whitish cut surface and firm consistency. It
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infiltrated the upper major calyx and infundibulum. The
tumor corresponded well to the large solid mass detected on
US and CT scan. Another nodule, involving the upper renal
pole, bulging outward and invading the kidney capsule, was
found. It was 5 mm in maximum dimension with a white cut
surface. The adjacent renal parenchyma was normal, while
surgical margins, adrenal gland and exported loco-regional
lymph nodes were free of tumor involvement. 
Microscopic findings. Histologically, the medullar tumor
consisted of medium, uniform cells arranged in tubular
pattern (Figure 4) with desmoplastic stroma and a brisk
inflammatory reaction (Figure 5). The tumor cells had
round to oval nuclei with small inconspicuous nucleoli, and
fairly abundant and eosinophilic cytoplasm. Extensive
destruction of renal medullar tissue was found with
infiltration of the renal cortex glomeruli and dysplasia of the
collecting duct epithelium.
As previously described, another nodule involving the
renal cortex and invading the capsule was found. This
cortical nodule had a papillary growth pattern (Figure 6a)
with numerous psammoma bodies. The cells were uniform
with inconspicuous cytoplasm, ovoid nuclei and rare nucleoli.
Immunohistochemical studies. The tumor cells of the
medullar neoplasm reacted with antibodies to cytokeratin
pool CK19 and UEA-1 (Figure 7b,c). This is the staining
pattern of normal distal tubular epithelium. CK7 resulted
negative (Figure 7a). A focal, faint perceptible membrane
staining was found in less than 10% of the tumor cells, with
antibodies for c-erb B2 (Figure 7d). 
The tumor cell of the cortical neoplasm was strongly
positive for CK7 (Figure 6b).
Discussion
The coexistence of multiple synchronous primary neoplasms
in the same kidney has been rarely described in the
literature. The most frequent combination is RCC and
TCC. Hart et al. reviewed 22 cases reported in the English
literature (4). CDC was found to be associated with TCC (2
cases) (2) and with RCC (1 case) (3).
Bellini CDC represents a subgroup within renal
carcinoma with an incidence of 0.4-2% (2) of all renal
tumors. It is a rare neoplasm with less than 150 cases
described in the literature to date (5, 6), of which 41 were in
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Table I. Immunohistochemical panel of antibodies used for our case.
Ulex Europeus Agglutinin-1 UEA-1
Low molecular weight cytokeratin CK 7
Low molecular weight cytokeratin CK 19
Antibody for oncogene c-erb B2
Figure 1. CT-scan: a 5-cm-large renal
mass protruding into the central sinus
having minimal contrast enhancement. 
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Figure 3. Retrograde (high pressure) pyelography showing an endoluminal minus (arrow) causing obstruction of the upper collecting system.
Figure 2. Arteriography showing a completely avascular mass.
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Figure 4. CDC with tubular growth pattern.
Figure 5. CDC with desmoplastic stroma and inflammatory cells.
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Figure 6. CDC with most of the tumor cells displaying positive immunoperoxidase stain by CK 7 (a), CK19 (b), UEA-1 (c) and c-erb B2 antibodies (d)
(original magnification, x 400).
Figure 7. Papillary RCC with papillary growth pattern (a) and positive immunoperoxidase stain by CK7 antibodies (b) (original magnification, x200).
Japan (7-21). A review of the available Anglo-Saxon
literature reported about 64 cases (5). It occurs in a wide
age range and predominantly in males (6).
CDC is a highly aggressive renal tumor (22), with a poor
prognosis (mean survival 11.5 months (5)). Its histogenesis
is still a matter of debate although a putative origin from
collecting ducts has been proposed (14, 23-25). The
collecting ducts share their embryological origin in Wolf’s
duct with the calyces, renal pelvis and ureter (6). This
common embryological origin could justify its synchronous
or metachronous association with in situ or papillary TCC
in the adjacent renal pelvis (2), but not with papillary RCC.
In fact, while CDC originates in the medullar collecting
duct, a mesonephric structure, RCC originates from tissues
having metanephric precursors.
CDC seems to belong to a broad spectrum of distal
collecting duct carcinomas with different morphological
traits: low-grade CDC (McLennan et al. (26) described this
mucin-producing subtype of CDC) → CDC → renal
medullary carcinoma (6) showing worsening prognoses.
Genetic studies show that CDC is not clearly related to
clear renal cell carcinoma but may be of heterogeneous
origin: loss of heterozygosity of von Hippel Lindau gene
(3p), of p16 (9p) and of p53 (17p) (25); loss of DNA
sequences involving chromosomes 1, 2, 9, 11 and 18 and
gain of DNA sequences affecting chromosome 16 and 20
were reported (27). Eighteen collecting duct carcinomas
were studied by Polascik et al. (1) using highly informative
microsatellite markers on all autosomal arms. This work
suggests that the molecular events that contribute to the
development of distal nephron tumors are distinct from
those associated with the ethiology of proximal tubule renal
cancer. The high incidence of c-erb B2 oncogene
amplification in CDC further characterizes this tumor as a
separate entity from renal cell carcinoma, and shows some
genetic characteristics in common with TCC (28).
Reviewing the literature, we found only one other
reference reporting the coexistence of CDC with RCC (3).
Ours seems to be the first case with coexisting papillary
RCC and CDC. Moreover, the patient also had a story of a
previous low-grade bladder TCC.
The usual histopatological pattern of CDC is that of a
tubular or tubulopapillary carcinoma with a desmoplastic
stroma that often contains neutrophils (6, 29). Besides
marked desmoplastic reaction, atypical hyperplastic changes
can be found in the adjacent collecting ducts (30). Although
light microscopy permits diagnosis of CDC on the basis of
its histomorphological features, CDC can be confused
histologically with other usual papillary RCCs (31). Thus,
immunohistochemical identification of specific antigens is
needed for differential diagnosis (6, 29-32). Positive
immunohistochemical staining with a collecting duct marker
(UEA-1) and distal tubule marker (EMA) and negative
staining with a proximal tubule marker (Leu M1) are highly
indicative of CDC (14, 17, 30, 31, 33).
Urinary cytology in CDC is another debated item:
Nguyen and Schumann (15) reported that urine sediments
of two reported cases with confirmed CDC showed
malignant glandular cells in sheets with defined, variable,
granular cytoplasm and oval, hyperchromatic nuclei
containing micro- or macronucleoli. Fallick et al. (34)
described a case of CDC associated with abnormal urine
cytology yet not typical of TCC, suggesting a close
relationship between the cytology and histology of this
uncommon malignancy. Finally, Zaman et al. (35) reported
that cytological specimens in two out of three patients who
underwent resection for CDC were interpreted as TCC and
one as reactive change. 
CDC spreads aggressively and many patients have
metastases at the time of presentation (6). Bone and lung
metastasis and also extensive regional node involvement were
reported (31). A fatal CDC, presenting with pleural
metastases, arising from the right kidney in an 8-year-old
child, was reported by Craver (34), while direct invasion of the
liver was reported by Sue et al. (17), thus requiring radical
nephrectomy and segmental hepatectomy. One case of tumor
extension into the inferior vena cava was also described (16).
Although, according to some authors (2, 11), CDC should
be suspected in cases when CT shows kidney maintaining the
normal outer contours, with mass protruding into the central
sinus and showing minimal contrast enhancement, often
diagnosis is possible only after surgery. There are very few
reports describing the tumor appearance at arteriography
(10, 14). Some authors (7, 19) reported 67Gallium citrate
uptake showing a potential utility of 67Ga scintigraphy in
detecting Bellini CDC.
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Table II. Long-term disease-free survival CDC patients in the reported
series (review of the literature).
Staging (TNM 1997)
and Fuhrman grade Survival
Chao et al.5 T1 G2 N0 5 yrs
Peyromaure et al.31 T1 Gx N0 13 mos
T3 Gx N0 17 mos
Méjean et al.37 T3b G3 N0 100 mos
T1 G4 N0 99 mos
Dobronski et al.38 T3 Gx N0 12 mos
Matsumoto et al.12 T1a Gx N0 24 mos
de la Pena Zarzuelo et al.39 T1 G2 N0 41 mos
T1 G2 N0 56 mos
T3a G3 N0 32 mos
T3a G3 N0 24 mos
Our patient T1(m) G3 N0 57 mos
In non metastatic patients, nephrectomy seems to be the
therapy of choice as the tumor usually displays highly
aggressive behavior (10, 23, 36). Nevertheless, if imagistic
procedures (67Gallium imaging included) are suggestive of
CDC, biopsy should be performed, as nephrectomy seems
less useful in metastatic CDC (37). Some authors have
proposed and performed adjuvant chemotherapy, usually
employing TCC-indicated-for regimens: M-VAC (10, 18),
doxorubicin + gemcitabine alternated with ifosfamide
paclitaxel and cisplatin (CDDP) (22) and, recently, CDDP-
gemcitabine regimen (32). Some complete response was
reported (32), but relapse after chemotherapy is far from
being uncommon. Interferon-· or IL-2 immunotherapy
seems to have little effect in the adjuvant setting (32, 37)
even if episodical responses were reported (31, 36). The role
of adjuvant chemotherapy (21, 30) needs further evaluation
and prognosis still remains poor.
This aggressive tumor has dismal prognosis and early
diagnosis appears to be the only factor that may positively
influence the survival. In the most conspicuous series,
reported overall survival varied from 6-8 months (37), 11.5
months (5), to 20 months (39). 
Long-term disease-free survival was however reported,
particularly recently (Table II) in patients with non
metastatic disease. In fact, ours is one of the few cases (i.e.
5) reported in the literature having a survival of more than
4 years, still without any sign of relapse.
Conclusion
Collecting duct carcinoma is a rare renal cancer subtype; its
association with other renal tumors is found exceptionally.
In most of the cases, it has aggressive course and poor
prognosis. In recent literature reviews, some cases with good
outcome were, however, described. Current standard
chemotherapy or immunotherapy treatment regimens have
been found to be ineffective. Moreover, in case of
metastatic CDC, even nephrectomy seems not to be useful
except for palliative reasons. 
References
1 Polascik TJ, Cairns P, Epstein JI, Fuzesi L, Ro JY, Marshall FF,
Sidransky D and Schoenberg M: Distal nephron renal tumors:
microsatellite allelotype. Cancer Res 56(8): 1892-5, 1996.
2 Pereira Aria JG, Ateca Diaz-Obregon R, Guttierez Dies JM,
Ramirez Rodriguez MM, Etxezarrazga Zuluaga MC and
Berreteaga Gallastegui JR: Synchronous association of Bellini
ducts and pyelic transitional carcinoma, Actas Urol Esp 21(10):
990-6, 1997.
3 Auget T, Milona JC, Lorenzo A, Vila J, Sirvent JJ and Richart
C: Synchronus renal cell carcinoma and Bellini duct carcinoma:
a case report on a rare coincidence. World J Urol 18(6): 449-
51, 2000.
4 Hart AP, Brown R, Lechago J and Troung DL: Collision of
transitional cell carcinoma and renal cell carcinoma. Cancer
73(1): 154-9, 1994.
5 Chao D, Zisman A, Patruck AJ, Gitlitz BJ, Freedland SJ, Said JW,
Figlin RA and Belldegrun AS: Collecting duct renal cell
carcinoma: clinical study of a rare tumor. J Urol 167(1): 71-4, 2002.
6 Srigley JR and Eble JN: Collecting duct carcinoma of kidney.
Semin Diagn Pathol 15(1): 54-67, 1998. 
7 Gotoh E, Ohishi A and Kawakami K: Ga-67 imaging in a rare
case of Bellini duct carcinoma. Clin Nucl Med 23(1): 46-7, 1998.
8 Inagaki T, Hagina K, Matsumura N, Koh M, Nishikawa T,
Suzuki A and Hirano A: A case of collecting duct carcinoma
(Bellini duct carcinoma) producing carcinoembryonar antigen.
Hinyokika Kiyo 47(3): 183-6, 2001.
9 Kawanishi H, Aoyama T, Yoshida T, Sasaki M and Itoh T:
Bellini duct carcinoma of the kidney: a case report. Hinyokika
Kiyo 46(6): 401-4, 2000.
10 Jinza S, Asakura T, Takase K, Misaki H, Satomi Y and
Nagashima Y: Bellini duct carcinoma of kidney with invasive
growth pattern: a case report. Hinyokika Kiyo 43(4): 291-4, 1997.
11 Fukuya T, Honda H, Goto K, Ono M, Matsuura T, Kaneko K,
Kuroiwa T, Yoshimitsu K, Irie H, Yoshida J, Naito S and
Masuda K: CT findings of Bellini duct carcinoma of the kidney.
J Comput Assist Tomogr 20(3): 399-403, 1996. 
12 Matsumoto H, Wada T, Aoki A, Hoshii Y, Takahashi M, Aizawa
S and Naito K: Collecting duct carcinoma with long survival
treated by partial nephrectomy. Int J Urol 8(7): 401-3, 2001.
13 Morikawa H, Yamada Y, Oda H, Kitahara K, Kanemura M and
Komatsu H: A case of Bellini duct carcinoma producing
granulocyte colony-stimulating factor (G-CSF). Hinyokika Kiyo
47(7): 485-7, 2001.
14 Natsume O, Futami T and Ohta M: Bellini duct carcinoma: a
case report. Jpn J Clin Oncol 27(2): 107-10, 1997. 
15 Nguyen GK and Schumann GB: Cytopathology of renal
collecting duct carcinoma in urine sediment. Diagn Cytopathol
16(5): 446-9, 1997. 
16 Oida T, Takenava J, Okura K and Watanabe C: Collecting duct
carcinoma (Bellini duct carcinoma) of the kidney with extension
into the inferior vena cava. Hinyokika Kiyo 45(7): 473-6, 1999.
17 Sue Y, Kuneida M, Yamaguchi S, Hashimoto H and Yachigu
S: Bellini duct carcinoma of the kidney: a case report.
Hinyokika Kiyo 43(3): 213-6, 1997. 
18 Sumi Y, Ozahi Y, Shindoh N and Katayama H: Gallium-67
uptake in Bellini duct carcinoma of the kidney. Ann Nucl Med
13(2): 117-20, 1999.
19 Suzuki K and Tokue A: Immunohistochemical study of bcl-2,
p53 and Ki-67 expressions in collecting duct carcinoma of the
kidney. Five cases and review of the literature on bcl-2, p53 and
Ki-67 expressions in renal cell carcinoma and transitional cell
carcinoma. Urol Int 69(1): 57-62, 2002.
20 Sugimoto K, Tsuji H, Negita M, Nagai N, Nose K and Kurita
T: Bellini duct carcinoma of the kidney: a case report.
Hinyokika Kiyo 44(8): 587-9, 1998. 
21 Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N and
Nanus DM: Active CT for CDC of the kidney: a case report
and review of the literature. Cancer 94(1): 111-6, 2002.
22 Cavazzana AO, Prayer-Galetti T, Tirabosco R, Macciomei MC,
Stella M, Lania L, Cannada-Bartoli P, Spagnoli LG, Passerini
Glazel G and Pagano F: Bellini duct carcinoma. A clinical and
in vitro study. Eur Urol 30(3): 340-4, 1996. 
Matei et al: Synchronous Collecting Duct Carcinoma and Papillary Renal Cell Carcinoma
585
23 Prati GF, Dean P, Firpo M, Moscatelli P, Saggin P and Muolo
A: Bellini duct (collecting duct) carcinoma of the kidney. Int
Urol Nephrol 30(6): 677-80, 1998. 
24 Fogt F, Zhuang Z, Linehan WM and Merino MJ: Collecting
duct carcinomas of the kidney: a comparative loss of
heterozygosity study with clear cell renal cell carcinoma. Oncol
Rep 5(4): 923-6, 1998. 
25 McLennan GT, Farrow GM and Bostwick DG: Low-grade
collecting duct carcinoma of the kidney: report of 13 cases of
low-grade mucinous tubulocystic renal carcinoma of possible
collecting duct origin. Urology 50: 679-84, 1997.
26 Verdorfer I, Culing Z, Hobish A, Bartsch G, Hittmair A, Duba
HC and Erdel M: Characterisation of a collecting duct
carcinoma by cytogenetic analysis and comparative genomic
hybridisation. Int J Oncol 13(3): 461-4, 1998.
27 Selli C, Amorosi A, Vona G, Sestini R, Travaglini F, Bartoletti
R and Orlando C: Retrospective evaluation of c-erb B-2
oncogene amplification using competitive PCR in collecting
duct carcinoma of kidney. J Urol 158(19): 245-7, 1997. 
28 Bejar J, Szvalb S, Maly B, Munichor M and Cohen H:
Collecting duct carcinoma of kidney: a cytological study and
case report. Diagn Cytopathol 15(2): 136-8, 1996
29 Tulunay O, Kupeli S and Okcu AH: Collecting duct carcinoma.
Urol Int: 67: 86-90, 2001. 
30 Kirkaly Z, Celebi I, Akan G and Yorukoglu K: Bellini duct
(collecting duct) carcinoma of the kidney. Urology 47(6): 921-
3, 1996. 
31 Peyromaure M, Thioun N, Scotté F, Vieillefond A, Debré B
and Oudard S: Collecting duct carcinoma of the kidney: a
clinicopathological study of 9 cases. J Urol 170: 1138-40, 2003.
32 Craver RD, Correa H, Crapanzano JP, Kumar SR and Gardner
RV: Renal collecting duct carcinoma in an 8-year-old child.
Pediatr Nephrol 10(1): 29-32, 1996. 
33 Fallick ML, Hutchinson M, Alroy J and Long JP: Collecting-
duct carcinoma presenting as upper tract lesion with abnormal
urine cytology. Diagn Cytopathol 16(3): 258-61, 1997. 
34 Mattelaer P, Wolff JM, Ijzerman W, Fuzesi L and Jakse G:
Bellini duct carcinoma: a rare variant of renal cell carcinoma.
Acta Urol Belg 64(3): 33-5. 1996. 
35 Zaman SS, Sack MJ, Ramchandani P, Tomaszewski JE and
Gupta PK: Cytopathology of retrograde renal pelvis brush
specimens: an analysis of 40 cases with emphasis on collecting
duct carcinoma and low-intermediate grade transitional cell
carcinoma. Diagn Cytopathol 15(4): 312-21, 1996. 
36 Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato
R and Ro J: Collecting duct carcinoma of the kidney. Br J Urol
71: 388-91, 1993
37 Mèjean A, Rouprêt M, Larousserie F, Hopirtean V, Thiounn
N and Dufour B: Is there place for radical nephrectomy in the
presence of metastatic collecting duct (Bellini) carcinoma? J
Urol 169: 1287-90, 2003.
38 Dobronski P, Czaplicki M, Kozminska E and Pykalo R:
Collecting (Bellini) duct carcinoma of the kidney – clinical,
radiologic and immunohistochemical findings. Int Urol Nephrol
31(5): 601-9, 1999.
39 de la Pena Zazuelo E, Moreno Sierra J, Boccardo Fajardo G,
Redondo Gonzales E, Silmi Moyano A, Aguilar Rivilla E and
Resel Estevez L: Collecting duct carcinoma. Personal
experience and review of the literature. Arch Esp Urol 55(3):
275-83, 2002.
Received August 10, 2004
Accepted December 30, 2004
ANTICANCER RESEARCH 25: 579-586 (2005)
586
